Bacterial vaginosis-associated microbiota (BVAB) (BVAB)

Bacterial vaginosis-associated microbiota represents a dysbiotic state characterized by the depletion of lactic acid-producing Lactobacillus species and an overgrowth of diverse anaerobic bacteria (Fredricks et al., 2005, New England Journal of Medicine). This polymicrobial population includes Gardnerella vaginalis, Atopobium vaginae, and various Clostridiales-like organisms termed BV-associated bacteria 1, 2, and 3 (BVAB1-3) (Fredricks et al., 2005). These organisms often organize into resilient biofilms on the vaginal epithelium, which are implicated in high rates of treatment failure and recurrence (Swidsinski et al., 2005, Obstetrics & Gynecology). The metabolic activity of these bacteria produces malodorous amines and degradative enzymes like sialidases, which compromise the vaginal mucosal barrier (Lewis et al., 2013, Journal of Biological Chemistry). Clinically, this target is addressed using antibiotics such as metronidazole and clindamycin, which aim to reduce the anaerobic burden, though they often fail to eradicate the underlying biofilm (Muzny et al., 2019, The Journal of Infectious Diseases). Emerging therapeutic approaches also target these populations through the use of probiotics or vaginal microbiota transplantation to restore a healthy microbial balance (Borges et al., 2014, Archives of Gynecology and Obstetrics).

Other names

BV-associated bacterial populationsVaginal dysbiosisBacterial vaginosis-associated bacteriaAnaerobic vaginal microbiotaBV-associated microbiota

Antibiotics like metronidazole and tinidazole act by disrupting DNA synthesis in anaerobic bacteria, while clindamycin inhibits protein synthesis by binding to the 50S ribosomal subunit (Workowski et al., 2021, MMWR Recommendations and Reports). Probiotic interventions aim to restore the dominance of Lactobacillus species through competitive exclusion and production of lactic acid and hydrogen peroxide (Borges et al., 2014, Archives of Gynecology and Obstetrics).